

ARRAY BIOPHARMA INC
Form 8-K
February 20, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2019

Array BioPharma Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-16633 84-1460811
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

3200 Walnut Street, Boulder, Colorado 80301
(Address of principal executive offices, including Zip Code)

303 381-6600
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 19, 2019, Curtis Oltmans notified Array that he will be resigning as Executive Vice President, General Counsel and Secretary of Array (“General Counsel”). Mr. Oltmans’s last day of employment with Array will be March 19, 2019. Mr. Oltmans’s resignation did not arise from any disagreement on any matter relating to Array’s operations, policies or practices.

Array’s Board of Directors has appointed Rogan P. Nunn as interim General Counsel effective February 19, 2019. Mr. Nunn will serve as Array’s interim General Counsel pursuant to an agreement with Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, where Mr. Nunn is a Senior Associate specializing in corporate law, securities law, corporate governance, mergers and acquisitions and complex transactions. Previously, Mr. Nunn held positions at Morgan Stanley and KPMG, LLP. Mr. Nunn holds a Bachelor of Science in Finance and International Business from Georgetown University and a Juris Doctor from the University of Virginia School of Law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 20, 2019 Array BioPharma Inc.

By: /s/ JASON HADDOCK
Jason Haddock
Chief Financial Officer